The rest of the 100 (in alphabetical order): Robert Creeden, managing director, UVA LVG Seed Fund
Robert Creeden joined the licensing and ventures group of University of Virginia (UVA) in 2016 as managing director of its $10m UVA Seed Fund.
The fund was set up with $5m from the university’s healthcare arm UVA Health System and contributions from unnamed private investors.
In its first year, the fund made investments of undisclosed size in three spinouts – diabetes management technology firm TypeZero, dry-eye disease therapy developer TearSolutions and cybersecurity firm Mission Secure.
Its fourth investment, 510 Kardiac Devices, a cardiovascular surgery device developer, was made in May this year in a round that also featured device manufacturer Nextern Medical.
The fund seeks to fill the capital gap for technologies that are at a stage too early for traditional funding sources.
Before being hired by UVA, Creeden was senior partner at consultancy Derby Management. He was also the founder of the Partners Innovation Fund, the corporate venturing arm of health system Partners HealthCare.